Larissa Mukankurayija

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background Enhancing throughput of bioprocess development has become increasingly important to rapidly screen and optimize cell culture process parameters. With increasing timeline pressures to get therapeutic candidates into the clinic, resource intensive approaches such as the use of shake flasks and bench-top bioreactors may limit the design space for(More)
Background Recombinant therapeutic proteins are usually produced by cell culture technology using genetically modified host cell lines. During the manufacturing process, a mixture of the protein of interest and host cell derived impurities, including host cell proteins (HCPs) and other process related impurities are produced. Those process related(More)
  • 1